{"protocolSection":{"identificationModule":{"nctId":"NCT01360554","orgStudyIdInfo":{"id":"A7471009"},"secondaryIdInfos":[{"id":"2010-022656-22","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","officialTitle":"Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy","acronym":"ARCHER 1009"},"statusModule":{"statusVerifiedDate":"2017-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-06-16"},"primaryCompletionDateStruct":{"date":"2013-09-30","type":"ACTUAL"},"completionDateStruct":{"date":"2015-09-14","type":"ACTUAL"},"studyFirstSubmitDate":"2011-04-12","studyFirstSubmitQcDate":"2011-05-24","studyFirstPostDateStruct":{"date":"2011-05-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-09-07","resultsFirstSubmitQcDate":"2017-04-24","resultsFirstPostDateStruct":{"date":"2017-05-24","type":"ACTUAL"},"dispFirstSubmitDate":"2014-10-27","dispFirstSubmitQcDate":"2014-10-27","dispFirstPostDateStruct":{"date":"2014-11-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-04-24","lastUpdatePostDateStruct":{"date":"2017-05-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["comparative study of PF-00299804 and Erlotinib","Double-Blind Phase 3 trial of TKI"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":878,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","description":"Blinded active PF-00299804 + blinded placebo comparator (erlotinib)","interventionNames":["Drug: Dacomitinib (PF-00299804)","Drug: Placebo erlotinib"]},{"label":"B","type":"ACTIVE_COMPARATOR","description":"Blinded active comparator (erlotinib) + blinded placebo PF-00299804","interventionNames":["Drug: Active Comparator (erlotinib)","Drug: Placebo PF00299804"]}],"interventions":[{"type":"DRUG","name":"Dacomitinib (PF-00299804)","description":"Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing","armGroupLabels":["A"]},{"type":"DRUG","name":"Active Comparator (erlotinib)","description":"Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing","armGroupLabels":["B"]},{"type":"DRUG","name":"Placebo erlotinib","description":"placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.","armGroupLabels":["A"]},{"type":"DRUG","name":"Placebo PF00299804","description":"placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing","armGroupLabels":["B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS) Per Independent Radiologic Review.","description":"PFS was defined as the time from randomization to the date of disease progression as by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 per Independent Radiologic Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions.","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.","description":"PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Independent Radiologic Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions. Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy."}],"secondaryOutcomes":[{"measure":"PFS Based on Investigator Review.","description":"PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Investigator's Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions.","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"PFS Based on Investigator Review in KRAS-WT Participants.","description":"PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Investigator's Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions. Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"Overall Survival (OS).","description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive (ie, at their last known alive date from long term follow-up).","timeFrame":"From date of randomization until the date of death from any cause or last date known to be alive, participants were followed up regardless of the reason for discontinuation from study treatment at intervals of no longer than every 2 months."},{"measure":"OS in KRAS-WT Participants.","description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive (ie, at their last known alive date from long term follow-up). Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.","timeFrame":"From date of randomization until the date of death from any cause or last date known to be alive, participants were followed up regardless of the reason for discontinuation from study treatment at intervals of no longer than every 2 months."},{"measure":"Best Overall Response (BOR) Per Independent Radiologic Review.","description":"The BOR was the best response per RECIST (version 1.1) criteria as assessed by independent assessment recorded from randomization until disease progression. Per RECIST version 1.1: Complete Response (CR): disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; Partial Response (PR): \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; Progressive Disease (PD): \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","timeFrame":"From date of randomization until progression or initiation of new anti-cancer therapy or death. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"BOR Per Investigator Review.","description":"The BOR was the best response per RECIST (version 1.1) criteria as assessed by investigator assessment recorded from randomization until disease progression. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","timeFrame":"From date of randomization until progression or initiation of new anti-cancer therapy or death. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"Duration of Response (DR) Based on Independent Radiologic Review.","description":"DR was defined as the time from first documentation of response assessed by independent review (CR or PR whichever occurred first) to date of progression or death due to any cause, whichever occurs first. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","timeFrame":"From date of randomization until progression or death due to any cause. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"DR Based on Investigator Review.","description":"DR was defined as the time from first documentation of response assessed by investigator review (CR or PR whichever occurred first) to date of progression or death due to any cause, whichever occurs first. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","timeFrame":"From date of randomization until progression or death due to any cause. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy."},{"measure":"Trough Concentrations (Ctrough) of Dacomitinib.","description":"Mean Ctrough values of dacomitinib observed from Cycle 2 through 5, Day 1 for dose compliant participants.","timeFrame":"Baseline up to Cycle 5 Day 1"},{"measure":"Trough Concentrations (Ctrough) of PF-05199265.","description":"Mean Ctrough values of PF-05199265 observed from Cycle 2 through 5, Day 1 for dose compliant participants.","timeFrame":"Baseline up to Cycle 5 Day 1"},{"measure":"Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough Patient Reported Disease Symptoms.","description":"TTD defined as the time from first dose (baseline) to the first time a patient's score in pain, dyspnea, fatigue or cough from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-LC13) increased by ≥10 points. A ≥10 point increase in score had to be maintained for ≥2 consecutive cycles for the symptom to be considered deteriorated. Participants were censored at the last time when they completed an assessment for pain, dyspnea, fatigue or cough if they had not deteriorated. A 10 point or higher change in the score is perceived by participants as clinically significant.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal."},{"measure":"Mean and Difference in Mean in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Scores ranged from 0-100 where a higher score indicated a better level of quality of life. Overall scores present the mean score for that scale from all time-point data.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores."},{"measure":"Mean and Difference in Mean in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30.","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Scores ranged from 0-100 where a higher score indicated a greater degree of symptoms/problems. Overall scores present the mean score for that scale from all time-point data.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores."},{"measure":"Mean and Difference in Mean in Lung Cancer Symptom Scores as Assessed by the EORTC QLQ- LC13.","description":"The QLQ-LC13 included questions specific to the disease associated symptoms (dyspnea, cough, haemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy, and alopecia), and analgesic use of lung cancer patients. Scores range from 0-100 and a higher score indicates greater degree of symptoms/problems. Overall scores present the mean score for that scale from all time-point data.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores."},{"measure":"Mean and Difference in Mean of the EuroQoL-5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Score","description":"The EQ-5D is a validated and reliable self-report preference-based measure developed by the EuroQoL Group to assess health-related quality of life. It consists of the EQ-5D descriptive system and a visual analogue scale-the EQ VAS. The EQ-5D descriptive system measures a participants' health state on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels, reflecting \"no health problems,\" \"moderate health problems,\" and \"extreme health problems.\" The EQ VAS records the respondent's self-rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Evidence of pathologically confirmed, advanced NSCLC (with known histology).\n* Prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced NSCLC).\n* Adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.\n* Adequate renal, hematologic, liver function.\n* ECOG PS of 0-2.\n* Radiologically measurable disease.\n\nExclusion Criteria:\n\n* Small cell histology.\n* Symptomatic brain mets or known leptomeningeal mets.\n* Prior therapy with agent known or proposed to be active by action on EGFR tyrosine kinase or other HER family proteins.\n* Uncontrolled medical disorders.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35249","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Northwest Alabama Cancer Center","city":"Florence","state":"Alabama","zip":"35630","country":"United States","geoPoint":{"lat":34.79981,"lon":-87.67725}},{"facility":"University of South Alabama Mitchell Cancer Institute","city":"Mobile","state":"Alabama","zip":"36604","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"University of South Alabama Medical Center","city":"Mobile","state":"Alabama","zip":"36617","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Northwest Alabama Cancer Center","city":"Muscle Shoals","state":"Alabama","zip":"35661","country":"United States","geoPoint":{"lat":34.74481,"lon":-87.66753}},{"facility":"Ironwood physicians P C dba Ironwood Cancer & Research Centers","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers","city":"Gilbert","state":"Arizona","zip":"85297","country":"United States","geoPoint":{"lat":33.35283,"lon":-111.78903}},{"facility":"Desert Oncology Associates dba Ironwood Cancer and Research Centers","city":"Mesa","state":"Arizona","zip":"85202","country":"United States","geoPoint":{"lat":33.42227,"lon":-111.82264}},{"facility":"Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers","city":"Mesa","state":"Arizona","zip":"85206","country":"United States","geoPoint":{"lat":33.42227,"lon":-111.82264}},{"facility":"Highlands Oncology Group PA","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"Highlands Oncology Group, PA","city":"Rogers","state":"Arkansas","zip":"72758","country":"United States","geoPoint":{"lat":36.33202,"lon":-94.11854}},{"facility":"Central Hematology Oncology Medical Group Inc.","city":"Alhambra","state":"California","zip":"91801","country":"United States","geoPoint":{"lat":34.09529,"lon":-118.12701}},{"facility":"UCLA Hematology Oncology-Alhambra","city":"Alhambra","state":"California","zip":"91801","country":"United States","geoPoint":{"lat":34.09529,"lon":-118.12701}},{"facility":"City of Hope","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"St. Jude Heritage Healthcare","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"Drug Management Only","city":"Los Angeles","state":"California","zip":"90095-1772","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Drug Managerrent Only:","city":"Los Angeles","state":"California","zip":"90095-1772","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"UCLA West Medical Pharmacy","city":"Los Angeles","state":"California","zip":"90095-1772","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Administrative Address: UCLA Hematology Oncology-Clinical Research Unit (CRU)","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Drug Shipment Address: Ronald Reagan UCLA Medical Center, Drug Information Center","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Regulatory Management Only:","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Regulatory Management:","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Ronald Reagan UCLA Medical Center","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"TORI Central Administration","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Westwood Bowyer Clinic, Peter Morton Medical Building","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"UCLA/Pasadena Healthcare Hematology-Oncology","city":"Pasadena","state":"California","zip":"91105","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Central Hematology Oncology Medical Group, Inc.","city":"Pasadena","state":"California","zip":"91107","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Cancer Care Associates Medical Group Inc.","city":"Redondo Beach","state":"California","zip":"90277","country":"United States","geoPoint":{"lat":33.84918,"lon":-118.38841}},{"facility":"Central Coast Medical Oncology Corporation","city":"Santa Maria","state":"California","zip":"93454","country":"United States","geoPoint":{"lat":34.95303,"lon":-120.43572}},{"facility":"UCLA Hematology Oncology-Parkside","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"UCLA Hematology Oncology-Santa Monica","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"UCLA Santa Monica Medical Center & Orthopedic Hospital","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"City of Hope South Pasadena Cancer Center","city":"South Pasadena","state":"California","zip":"91030","country":"United States","geoPoint":{"lat":34.11612,"lon":-118.15035}},{"facility":"UCLA/Santa Clarita Valley Cancer Center","city":"Valencia","state":"California","zip":"91355","country":"United States","geoPoint":{"lat":34.44361,"lon":-118.60953}},{"facility":"UCLA Cancer Center","city":"Westlake Village","state":"California","zip":"91361","country":"United States","geoPoint":{"lat":34.14584,"lon":-118.80565}},{"facility":"Norwalk Hospital","city":"Norwalk","state":"Connecticut","zip":"06856","country":"United States","geoPoint":{"lat":41.1176,"lon":-73.4079}},{"facility":"Florida Hospital","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Cancer Institute of Florida","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Hematology and Oncology Consultants, P.A.","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Investigational Drug Services, Florida Hospital","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Hematology Oncology Associates of the Treasure Coast","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"Emory University Hospital Midtown","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory Clinic","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory University Hospital","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Winship Cancer Institute of Emory University","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Northwest Georgia Oncology Centers, P.C.","city":"Austell","state":"Georgia","zip":"30106","country":"United States","geoPoint":{"lat":33.81261,"lon":-84.63438}},{"facility":"Northwest Georgia Oncology Centers, P.C.","city":"Carrollton","state":"Georgia","zip":"30117","country":"United States","geoPoint":{"lat":33.58011,"lon":-85.07661}},{"facility":"Northwest Georgia Oncology Centers, PC","city":"Cartersville","state":"Georgia","zip":"30121","country":"United States","geoPoint":{"lat":34.16533,"lon":-84.80231}},{"facility":"John B. Amos Cancer Center","city":"Columbus","state":"Georgia","zip":"31904","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Atlanta Cancer Care","city":"Decatur","state":"Georgia","zip":"30033","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"facility":"Georgia Cancer Specialists","city":"Decatur","state":"Georgia","zip":"30033","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"facility":"The Cancer Center at DeKalb Medical","city":"Decatur","state":"Georgia","zip":"30033","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"facility":"Northwest Georgia Oncology Centers, P.C.","city":"Douglasville","state":"Georgia","zip":"30134","country":"United States","geoPoint":{"lat":33.7515,"lon":-84.74771}},{"facility":"Suburban Hematology-Oncology Associates, P.C.","city":"Duluth","state":"Georgia","zip":"30096","country":"United States","geoPoint":{"lat":34.00288,"lon":-84.14464}},{"facility":"Northeast Georgia Medical Center","city":"Gainesville","state":"Georgia","zip":"30501","country":"United States","geoPoint":{"lat":34.29788,"lon":-83.82407}},{"facility":"Oncology Specialists of North Georgia, LLC","city":"Gainesville","state":"Georgia","zip":"30501","country":"United States","geoPoint":{"lat":34.29788,"lon":-83.82407}},{"facility":"The Longstreet Clinic Cancer Center","city":"Gainesville","state":"Georgia","zip":"30501","country":"United States","geoPoint":{"lat":34.29788,"lon":-83.82407}},{"facility":"Suburban Hematology-Oncology Associates, P.C.","city":"Lawrenceville","state":"Georgia","zip":"30046","country":"United States","geoPoint":{"lat":33.95621,"lon":-83.98796}},{"facility":"Northwest Georgia Oncology Centers, P.C.","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Suburban Hematology-Oncology Associates, P.C.","city":"Snellville","state":"Georgia","zip":"30078","country":"United States","geoPoint":{"lat":33.85733,"lon":-84.01991}},{"facility":"Illinois Cancer Specialists","city":"Arlington Heights","state":"Illinois","zip":"60005","country":"United States","geoPoint":{"lat":42.08836,"lon":-87.98063}},{"facility":"Ingalls Memorial Hospital - In-Patient Pharmacy","city":"Harvey","state":"Illinois","zip":"60426","country":"United States","geoPoint":{"lat":41.61003,"lon":-87.64671}},{"facility":"Ingalls Memorial Hospital","city":"Harvey","state":"Illinois","zip":"60426","country":"United States","geoPoint":{"lat":41.61003,"lon":-87.64671}},{"facility":"Monroe Medical Associates","city":"Harvey","state":"Illinois","zip":"60426","country":"United States","geoPoint":{"lat":41.61003,"lon":-87.64671}},{"facility":"Illinois Cancer Specialists","city":"Niles","state":"Illinois","zip":"60714","country":"United States","geoPoint":{"lat":42.01892,"lon":-87.80284}},{"facility":"Monroe Medical Associates","city":"Tinley Park","state":"Illinois","zip":"60477","country":"United States","geoPoint":{"lat":41.57337,"lon":-87.78449}},{"facility":"Deaconess Clinic Downtown","city":"Evansville","state":"Indiana","zip":"47713","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Monroe Medical Associates","city":"Munster","state":"Indiana","zip":"46321","country":"United States","geoPoint":{"lat":41.56448,"lon":-87.51254}},{"facility":"Cedar Valley Medical Specialists, P.C.","city":"Waterloo","state":"Iowa","zip":"50701","country":"United States","geoPoint":{"lat":42.49276,"lon":-92.34296}},{"facility":"Kentucky Cancer Clinic","city":"Hazard","state":"Kentucky","zip":"41701-9466","country":"United States","geoPoint":{"lat":37.24954,"lon":-83.19323}},{"facility":"University Medical Center, Inc.","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"University Medical Center, Inc","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Baptist Hospital East","city":"Louisville","state":"Kentucky","zip":"40207","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Karmanos Cancer Institute at Farmington Hills","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"North Mississippi Hematology and Oncology Associates, Ltd.","city":"Starkville","state":"Mississippi","zip":"39759","country":"United States","geoPoint":{"lat":33.45049,"lon":-88.81961}},{"facility":"North Mississippi Hematology and Oncology Associates, Ltd.,","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"Siteman Cancer Center-St. Peters","city":"City of Saint Peters","state":"Missouri","zip":"63376-1645","country":"United States","geoPoint":{"lat":38.80033,"lon":-90.62651}},{"facility":"Siteman Cancer Center-West County","city":"Creve Coeur","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.66089,"lon":-90.42262}},{"facility":"Barnes Jewish Hospital","city":"St Louis","state":"Missouri","zip":"63110-1094","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Washington University School of Medicine-IDS Pharmacy","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Dartmouth-Hitchcock Medical Center /Mary Hitchcock Memorial Hospital","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"Oncology and Hematology Specialists, P.A.","city":"Denville","state":"New Jersey","zip":"07834","country":"United States","geoPoint":{"lat":40.89232,"lon":-74.47738}},{"facility":"Stony Brook University-Cancer Center","city":"Stony Brook","state":"New York","zip":"11794-9447","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"facility":"Carolina Oncology Specialists PA","city":"Hickory","state":"North Carolina","zip":"28602","country":"United States","geoPoint":{"lat":35.73319,"lon":-81.3412}},{"facility":"Carolina Oncology Specialists PA","city":"Lenoir","state":"North Carolina","zip":"28645","country":"United States","geoPoint":{"lat":35.91402,"lon":-81.53898}},{"facility":"Mercy clinic oklahoma communities, Inc. - Mercy clinic oncology/Hematology - Norman","city":"Norman","state":"Oklahoma","zip":"73071","country":"United States","geoPoint":{"lat":35.22257,"lon":-97.43948}},{"facility":"Mercy Physicians of Oklahoma-Communities, Inc. - Mercy Clinic Oncology/Hematology - McAuley","city":"Oklahoma City","state":"Oklahoma","zip":"73120-8347","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Mercy Hospital Oklahoma City - Oncology Infusion","city":"Oklahoma City","state":"Oklahoma","zip":"73120","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Good Samaritan Hospital Samaritan Ambulatory Infusion Services","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Samaritan Hematology & Oncology Consultants","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Samaritan Pharmacy Services","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Samaritan North Lincoln Hospital","city":"Lincoln City","state":"Oregon","zip":"97367","country":"United States","geoPoint":{"lat":44.95816,"lon":-124.01789}},{"facility":"Samaritan Pacific Communities Hospital","city":"Newport","state":"Oregon","zip":"97365","country":"United States","geoPoint":{"lat":44.63678,"lon":-124.05345}},{"facility":"Guthrie Clinic, Limited","city":"Sayre","state":"Pennsylvania","zip":"18840","country":"United States","geoPoint":{"lat":41.97896,"lon":-76.5155}},{"facility":"Robert Packer Hospital","city":"Sayre","state":"Pennsylvania","zip":"18840","country":"United States","geoPoint":{"lat":41.97896,"lon":-76.5155}},{"facility":"Texas Oncology-Longview Cancer Center","city":"Longview","state":"Texas","zip":"75601","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Texas Oncology-Tyler","city":"Tyler","state":"Texas","zip":"75702","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Texas Oncology - Waco","city":"Waco","state":"Texas","zip":"76712","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Kadlec Clinic Hematology and Oncology","city":"Kennewick","state":"Washington","zip":"99336","country":"United States","geoPoint":{"lat":46.21125,"lon":-119.13723}},{"facility":"Kadlec Medical Center","city":"Richland","state":"Washington","zip":"99352","country":"United States","geoPoint":{"lat":46.28569,"lon":-119.28446}},{"facility":"Outpatient Imaging Center","city":"Richland","state":"Washington","zip":"99352","country":"United States","geoPoint":{"lat":46.28569,"lon":-119.28446}},{"facility":"Seattle Cancer Care Alliance","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"University of Washington Medical Center","city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Sozialmedizinisches Zentrum Baumgartner Hoehe - Otto Wagner Spital und Pflegezentrum","city":"Vienna","zip":"1140","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Institut Jules Bordet","city":"Brussels","zip":"1000","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Laboratoire de la Porte de Hall","city":"Brussels","zip":"1000","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Grand Hopital de Charleroi Oncologie-Hematologie","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"CHU Ambroise Parre- Service Biologie Clinique","city":"Mons","zip":"7000","country":"Belgium","geoPoint":{"lat":50.45413,"lon":3.95229}},{"facility":"Heilig Hart Ziekenhuis Roeselare-Menen","city":"Roeselare","zip":"8800","country":"Belgium","geoPoint":{"lat":50.94653,"lon":3.12269}},{"facility":"Tumour Hospital of Guangxi Zhuang Autonomous Region","city":"Nanning","state":"Guangxi","zip":"530021","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"Union Hospital, Tongji Medical College of Huazhong University of Science & Technology/Cancer Center","city":"Wuhan","state":"Hubei","zip":"430023","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Jilin Provincial Cancer Hospital","city":"Changchun","state":"Jilin","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"West China Hospital of Sichuan University","city":"Chengdu","state":"Sichuan","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Shanghai Pulmonary Hospital","city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Aalborg Sygehus Syd","city":"Aalborg","zip":"9100","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Helsingin yliopistollinen sairaala, Meilahden kolmiosairaala, keuhkosairauksien poliklinikka","city":"Helsinki","zip":"00290","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Satakunnan keskussairaala/Keuhkosairauksien osasto A4","city":"Pori","zip":"28500","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"Centre Georges Francois Leclerc","city":"Dijon","zip":"21079","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"Hopital Albert Michallon","city":"Grenoble","zip":"38043","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"Hôpital Paris Saint Joseph","city":"Paris","zip":"75014","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"CHU de Poitiers","city":"Poitiers","zip":"86021","country":"France","geoPoint":{"lat":46.58261,"lon":0.34348}},{"facility":"Institut de Cancerologie de lOuest - Rene Gauducheau","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"Universitaetsklinikum Aachen","city":"Aachen","zip":"52074","country":"Germany","geoPoint":{"lat":50.77664,"lon":6.08342}},{"facility":"Asklepios Fachkliniken Muenchen-Gauting","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Lungenfachklinik Immenhausen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Universitaetsmedizin der Johannes Gutenberg-Universitaet","city":"Mainz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Krankenhaus Bethanien, Medizinische Klinik III","city":"Moers","zip":"47441","country":"Germany","geoPoint":{"lat":51.45342,"lon":6.6326}},{"facility":"University Hospital of Larissa","city":"Larissa","state":"Thessaly","zip":"41110","country":"Greece","geoPoint":{"lat":39.62847,"lon":22.42112}},{"facility":"Sotiria General Hospital of Athens","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"University Hospital of Heraklion","city":"Heraklion","zip":"71110","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"Semmelweis Egyetem Pulmonologiai Klinika","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum","city":"Debrecen","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Veszprem Megyei Onkormanyzat Tudogyogyintezete","city":"Farkasgyepű","zip":"8582","country":"Hungary","geoPoint":{"lat":47.2,"lon":17.63333}},{"facility":"Pandy Kalman Megyei Korhaz, Aktiv Tudogyogyaszat","city":"Gyula","zip":"5703","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft.","city":"Nyíregyháza","zip":"4412","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Zala Megyei Korhaz, Pulmonologiai Osztaly","city":"Zalaegerszeg-Pozva","zip":"8900","country":"Hungary"},{"facility":"Vedanta Institute of Medical Sciences","city":"Ahmedabad","state":"Gujarat","zip":"380 009","country":"India","geoPoint":{"lat":23.02579,"lon":72.58727}},{"facility":"Manipal Hospital","city":"Bangalore","state":"Karnataka","zip":"560017","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Tata Memorial Centre","city":"Mumbai","state":"Maharashtra","zip":"400012","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Ruby Hall Clinic","city":"Pune","state":"Maharashtra","zip":"411001","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"St Vincent's University Hospital","city":"Dublin","state":"Leinster","zip":"Dublin 4","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Beaumont Hospital","city":"Dublin","state":"Leinster","zip":"Dublin 9","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"St. James Hospital","city":"Dublin","zip":"8","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Oncology Department","city":"Waterford","country":"Ireland","geoPoint":{"lat":52.25833,"lon":-7.11194}},{"facility":"Aichi cancer center central hospital /Thoracic Oncology","city":"Nagoya","state":"Aichi-ken","zip":"464-8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"National Cancer Center Hospital East","city":"Kashiwa","state":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"National Hospital Organization Shikoku Cancer Center","city":"Matsuyama","state":"Ehime","zip":"791-0280","country":"Japan","geoPoint":{"lat":33.83916,"lon":132.76574}},{"facility":"National Hospital Organization Asahikawa Medical Center","city":"Asahikawa","state":"Hokkaido","zip":"070-8644","country":"Japan","geoPoint":{"lat":43.77063,"lon":142.36489}},{"facility":"Hyogo Cancer Center","city":"Akashi","state":"Hyōgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":34.65524,"lon":135.00687}},{"facility":"Kanazawa University Hospital","city":"Kanazawa","state":"Ishikawa-ken","zip":"9208641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Kanagawa Cardiovascular and Respiratory Center","city":"Yokohama","state":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Tohoku University Hospital","city":"Sendai","state":"Miyagi","zip":"980-8574","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Kurashiki Central Hospital","city":"Kurashiki","state":"Okayama-ken","zip":"710-8602","country":"Japan","geoPoint":{"lat":34.58333,"lon":133.76667}},{"facility":"Okayama University Hospital","city":"Okayama","state":"Okayama-ken","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Osaka City General Hospital Department of Clinical Oncology","city":"Osaka","state":"Osaka","zip":"534-0021","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Kinki University Hospital","city":"Osakasayama-shi","state":"Osaka","zip":"589-8511","country":"Japan"},{"facility":"National Hospital Organization Kinki-chuo Chest Medical Center","city":"Sakai-Shi","state":"Osaka","zip":"591-8555","country":"Japan"},{"facility":"Shizuoka Cancer Center","city":"Sunto-gun","state":"Shizuoka","zip":"411-8777","country":"Japan"},{"facility":"National Cancer Center Hospital","city":"Chuo-Ku","state":"Tokyo","zip":"104-0045","country":"Japan"},{"facility":"National Hospital Organization, Yamaguchi-Ube Medical Center","city":"Ube-shi","state":"Yamaguchi","zip":"755-0241","country":"Japan"},{"facility":"National Hp. Org. Kyushu Medical Center","city":"Fukuoka","zip":"810-8563","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"National Hospital Organization Kyushu Cancer Center/Department of Thoracic Oncology","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kyushu University Hospital Respiratory Medicine","city":"Fukuoka","zip":"812-8582","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"The Cancer Institute Hospital of JFCR","city":"Koto-ku, Tokyo","zip":"135-8550","country":"Japan"},{"facility":"Oaxaca Site Management Organization","city":"Oaxaca City","zip":"68000","country":"Mexico","geoPoint":{"lat":17.06025,"lon":-96.72544}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy","city":"Otwock","state":"Masovian Voivodeship","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Zoz All-Medi","city":"Otwock","state":"Masovian Voivodeship","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Nukleomed","city":"Warsaw","state":"Masovian Voivodeship","zip":"04-736","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"City Hospital #2 Krasnodar Multi-Field Diagnostic and Treatment Association","city":"Krasnodar","state":"Krasnodarskiy Kray","zip":"350012","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"facility":"Oncology Center # 2","city":"Sochi","state":"Krasnodarskiy Kray","zip":"354057","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"Federal State Healthcare Clinical Hospital #101 of the Federal Biomedical Agency","city":"Pyatigorsk","state":"Stavropolskij Kraj","zip":"357340","country":"Russia","geoPoint":{"lat":44.05,"lon":43.05036}},{"facility":"Pyatigorsk Oncology Center","city":"Pyatigorsk","zip":"357502","country":"Russia","geoPoint":{"lat":44.05,"lon":43.05036}},{"facility":"Clinic of Hospital Surgery","city":"Saint Petersburg","zip":"194044","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Military Medical Academy n.a. S.M.Kirov","city":"Saint Petersburg","zip":"194044","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"City Clinical Oncology Dispensary","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"St.-Petersburg State Medical University I.P.Pavlov of Roszdrav","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Institute of Pulmonology","city":"Saint Petersburg","zip":"197089","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Russian Scientific Center of Radiology and Surgical Technologies","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"City Clinical Oncology Dispensary","city":"Saint Petersburg","zip":"198255","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Samara Regional Clinical Oncology Dispensary","city":"Samara","zip":"443031","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"Univerzitna Nemocnica Bratislava, Klinika pneumologie a ftizeologie I- Oddelenie klinickej onkologie","city":"Bratislava","zip":"826 06","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Specializovana nemocnica sv. Svorada Zobor, n.o.","city":"Nitra","zip":"949 88","country":"Slovakia","geoPoint":{"lat":48.30763,"lon":18.08453}},{"facility":"Fakultna nemocnica s poliklinikou","city":"Nové Zámky","zip":"94034","country":"Slovakia","geoPoint":{"lat":47.98544,"lon":18.16195}},{"facility":"WCR: Wits Clinical Research","city":"Parktown,Johannesburg","state":"Gauteng","zip":"2193","country":"South Africa"},{"facility":"GVI Oncology Clinical Research Unit","city":"Kraaifontein","state":"Western Cape","zip":"7570","country":"South Africa","geoPoint":{"lat":-33.84808,"lon":18.71723}},{"facility":"Department of Oncotherapy","city":"Bloemfontein","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"facility":"GVI Oncology","city":"Port Elizabeth","zip":"6045","country":"South Africa","geoPoint":{"lat":-33.96109,"lon":25.61494}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"110-744","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center, Clinical Trial Center","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center, Department of Oncology","city":"Seoul","zip":"138-736","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital General Universitario de Elche - Edificio UIAE","city":"Elche","state":"Alicante","zip":"03203","country":"Spain","geoPoint":{"lat":38.26218,"lon":-0.70107}},{"facility":"Hospital Universitari Germans Trias i Pujol","city":"Badalona","state":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Hospital Provincial de Castellon - Servicio de Oncologia","city":"Castellon","state":"Castellon","zip":"12002","country":"Spain","geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"HOSPITAL DE LA SANTA CREU I SANT PAU - Pharmacy","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau - AGDAC","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau - Anatomia Patológica","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau - Diagnostic per la Imatge i Med. Nuclear","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau - Hospital de Día","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Provincial de Castellon (Farmacia)","city":"Castellon","country":"Spain","geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"Hospital Universitario 12 de Octubre-Radiology","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre01","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Madrid Sanchinarro","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen del Rocio. Hospital General Planta Baja. Servicio de Oncologia.","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"KPE/Onkologikliniken","city":"Karlstad","zip":"651 85","country":"Sweden","geoPoint":{"lat":59.3793,"lon":13.50357}},{"facility":"Karolinska Universitetssjukhuset","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Kantonsspital Aarau","city":"Aarau","zip":"5001","country":"Switzerland","geoPoint":{"lat":47.39254,"lon":8.04422}},{"facility":"Istituto Oncologico della Svizzera Italiana","city":"Bellinzona","zip":"06500","country":"Switzerland","geoPoint":{"lat":46.19278,"lon":9.01703}},{"facility":"Hopitaux Universitaires de Geneve","city":"Geneva","zip":"1211","country":"Switzerland","geoPoint":{"lat":46.20222,"lon":6.14569}},{"facility":"Ospedale Regionale di Locarno La Carita","city":"Locarno","zip":"06600","country":"Switzerland","geoPoint":{"lat":46.17086,"lon":8.79953}},{"facility":"Kantonsspital St. Gallen","city":"Sankt Gallen","zip":"9007","country":"Switzerland","geoPoint":{"lat":47.42391,"lon":9.37477}},{"facility":"Kent Oncology Centre","city":"Maidstone","state":"Kent","zip":"ME16 9QQ","country":"United Kingdom","geoPoint":{"lat":51.26667,"lon":0.51667}},{"facility":"New Cross Hospital - Royal Wolverhampton Hospital NHS Trust","city":"Wolverhampton","state":"West Midlands","zip":"WV10 0QP","country":"United Kingdom","geoPoint":{"lat":52.58547,"lon":-2.12296}},{"facility":"North Middlesex NHS Trust","city":"Edmonton","zip":"N18 1QX","country":"United Kingdom","geoPoint":{"lat":51.62561,"lon":-0.05798}},{"facility":"Leicester Royal Infirmary","city":"Leicester","zip":"LE1 5WW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Cancer Clinical Trials Unit","city":"London","zip":"NW1 2PQ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Christie Hospital NHS Trust, Department of Medical Oncology","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Christie Hospital NHS Trust","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Lung and Melanoma Research Team","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"26768165","type":"DERIVED","citation":"Ramalingam SS, O'Byrne K, Boyer M, Mok T, Janne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9. doi: 10.1093/annonc/mdv593. Epub 2016 Jan 13."},{"pmid":"25439691","type":"DERIVED","citation":"Ramalingam SS, Janne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. doi: 10.1016/S1470-2045(14)70452-8. Epub 2014 Oct 15."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7471009&StudyName=ARCHER%201009%20%3A%20A%20Study%20Of%20Dacomitinib%20%28PF-00299804%29%20Vs.%20Erlotinib%20In%20The%20Treatment%20Of%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20%0A"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"There were no significant study milestones following participant enrollment, but prior to group assignment.","recruitmentDetails":"The study was conducted at 134 sites with 878 participants randomized in a 1:1 ratio to 1 of 2 treatment arms, of these 872 were treated. Eligible participants who provided written informed consent and met all inclusion and exclusion criteria were assigned a Single Subject Identification number and randomized by the central randomization system.","groups":[{"id":"FG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"FG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Three participants were randomized but not treated.","numSubjects":"439"},{"groupId":"FG001","comment":"Three participants were randomized but not treated.","numSubjects":"439"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"436"},{"groupId":"FG001","numSubjects":"436"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"439"},{"groupId":"FG001","numSubjects":"439"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"359"},{"groupId":"FG001","numSubjects":"371"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"Study terminated by sponsor","reasons":[{"groupId":"FG000","numSubjects":"49"},{"groupId":"FG001","numSubjects":"37"}]},{"type":"Other, not specified","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Randomized but not treated.","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The baseline analysis population included all treated participants.","groups":[{"id":"BG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"BG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"436"},{"groupId":"BG001","value":"436"},{"groupId":"BG002","value":"872"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.3","spread":"9.57"},{"groupId":"BG001","value":"61.7","spread":"9.71"},{"groupId":"BG002","value":"62.5","spread":"9.67"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"311"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"286"},{"groupId":"BG001","value":"275"},{"groupId":"BG002","value":"561"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Per Independent Radiologic Review.","description":"PFS was defined as the time from randomization to the date of disease progression as by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 per Independent Radiologic Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions.","populationDescription":"The ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"439"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"1.9","upperLimit":"2.8"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.9","upperLimit":"2.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.195","pValueComment":"One-sided P-value.","statisticalMethod":"1-sided stratified log-rank test","statisticalComment":"Stratified by epidermal growth factor receptor (EGFR) status, Kirsten Rat Sarcoma status (KRAS), baseline Eastern Cooperative Oncology Group (ECOG).","paramType":"Hazard Ratio (HR)","paramValue":"0.933","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.797","ciUpperLimit":"1.093","estimateComment":"The HR (Dacomitinib arm versus erlotinib arm) and 95% CI were estimated from stratified Cox regression with EGFR status, KRAS, baseline ECOG as stratification factors."}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.","description":"PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Independent Radiologic Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions. Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.","populationDescription":"ITT population for KRAS-WT participants: all participants who were confirmed as having KRAS-WT tumors, randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"263"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"1.9","upperLimit":"2.9"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.9","upperLimit":"3.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.643","pValueComment":"One-sided P-value","statisticalMethod":"1-sided stratified log-rank test","statisticalComment":"Stratified by EGFR status and baseline ECOG.","paramType":"Hazard Ratio (HR)","paramValue":"1.037","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.848","ciUpperLimit":"1.268","estimateComment":"The HR (Dacomitinib arm versus erlotinib arm) and 95% CI were estimated from stratified Cox regression with EGFR status and baseline ECOG as stratification factors."}]},{"type":"SECONDARY","title":"PFS Based on Investigator Review.","description":"PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Investigator's Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions.","populationDescription":"The ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"439"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.9","upperLimit":"2.6"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.8","upperLimit":"2.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.069","pValueComment":"Stratified by EGFR status, KRAS status, and baseline ECOG.","statisticalMethod":"1-sided stratified log-rank test","statisticalComment":"One-sided P-value","paramType":"Hazard Ratio (HR)","paramValue":"0.899","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.780","ciUpperLimit":"1.035","estimateComment":"The HR (Dacomitinib arm versus erlotinib arm) and 95% CI were estimated from stratified Cox regression with EGFR status, KRAS status, and baseline ECOG as stratification factors."}]},{"type":"SECONDARY","title":"PFS Based on Investigator Review in KRAS-WT Participants.","description":"PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Investigator's Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions. Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.","populationDescription":"ITT population for KRAS-WT participants: all participants who were confirmed as having KRAS-WT tumors, randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"263"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.8","upperLimit":"2.7"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.8","upperLimit":"2.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.728","pValueComment":"One-sided P-value.","statisticalMethod":"1-sided stratified log-rank test","statisticalComment":"Stratified by EGFR status and baseline ECOG.","paramType":"Hazard Ratio (HR)","paramValue":"1.057","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.881","ciUpperLimit":"1.267","estimateComment":"The HR (Dacomitinib arm versus erlotinib arm) and 95% CI were estimated from stratified Cox regression with EGFR status and baseline ECOG as stratification factors."}]},{"type":"SECONDARY","title":"Overall Survival (OS).","description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive (ie, at their last known alive date from long term follow-up).","populationDescription":"The ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of death from any cause or last date known to be alive, participants were followed up regardless of the reason for discontinuation from study treatment at intervals of no longer than every 2 months.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"439"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"6.8","upperLimit":"9.0"},{"groupId":"OG001","value":"8.3","lowerLimit":"7.4","upperLimit":"9.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.638","pValueComment":"One-sided P-value.","statisticalMethod":"1-sided stratified log-rank test.","statisticalComment":"Stratified by EGFR status, KRAS status, and baseline ECOG.","paramType":"Hazard Ratio (HR)","paramValue":"1.026","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.887","ciUpperLimit":"1.188","estimateComment":"The HR (Dacomitinib arm versus erlotinib arm) and 95% CI were estimated from stratified Cox regression with EGFR status, KRAS status, and baseline ECOG as stratification factors."}]},{"type":"SECONDARY","title":"OS in KRAS-WT Participants.","description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive (ie, at their last known alive date from long term follow-up). Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.","populationDescription":"ITT population for KRAS-WT participants: all participants who were confirmed as having KRAS-WT tumors, randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of death from any cause or last date known to be alive, participants were followed up regardless of the reason for discontinuation from study treatment at intervals of no longer than every 2 months.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"263"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"6.7","upperLimit":"9.4"},{"groupId":"OG001","value":"8.5","lowerLimit":"7.5","upperLimit":"10.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.775","pValueComment":"One-sided P-value.","statisticalMethod":"1-sided stratified log-rank test.","statisticalComment":"Stratified by EGFR status and baseline ECOG.","paramType":"Hazard Ratio (HR)","paramValue":"1.078","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.886","ciUpperLimit":"1.312","estimateComment":"The HR (Dacomitinib arm versus erlotinib arm) and 95% CI were estimated from stratified Cox regression with EGFR status and baseline ECOG as stratification factors."}]},{"type":"SECONDARY","title":"Best Overall Response (BOR) Per Independent Radiologic Review.","description":"The BOR was the best response per RECIST (version 1.1) criteria as assessed by independent assessment recorded from randomization until disease progression. Per RECIST version 1.1: Complete Response (CR): disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; Partial Response (PR): \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; Progressive Disease (PD): \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","populationDescription":"The ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From date of randomization until progression or initiation of new anti-cancer therapy or death. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"439"}]}],"classes":[{"title":"Complete response","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}]}]},{"title":"Partial response","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"27"}]}]},{"title":"Stable/No response","categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"182"}]}]},{"title":"Objective progression","categories":[{"measurements":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"146"}]}]},{"title":"Indeterminate","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"76"}]}]}]},{"type":"SECONDARY","title":"BOR Per Investigator Review.","description":"The BOR was the best response per RECIST (version 1.1) criteria as assessed by investigator assessment recorded from randomization until disease progression. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","populationDescription":"The ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From date of randomization until progression or initiation of new anti-cancer therapy or death. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"439"}]}],"classes":[{"title":"Complete response","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Partial response","categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"42"}]}]},{"title":"Stable/No response","categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"136"}]}]},{"title":"Objective progression","categories":[{"measurements":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"206"}]}]},{"title":"Indeterminate","categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"52"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DR) Based on Independent Radiologic Review.","description":"DR was defined as the time from first documentation of response assessed by independent review (CR or PR whichever occurred first) to date of progression or death due to any cause, whichever occurs first. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","populationDescription":"DR was analyzed for a subgroup of participants in the ITT population, who had an objective tumor response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until progression or death due to any cause. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"35"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"6.9","upperLimit":"20.2"},{"groupId":"OG001","value":"10.1","lowerLimit":"5.6","upperLimit":"14.8"}]}]}]},{"type":"SECONDARY","title":"DR Based on Investigator Review.","description":"DR was defined as the time from first documentation of response assessed by investigator review (CR or PR whichever occurred first) to date of progression or death due to any cause, whichever occurs first. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \\>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \\>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.","populationDescription":"DR was analyzed for a subgroup of participants in the ITT population, who had an objective tumor response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until progression or death due to any cause. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"7.4","upperLimit":"16.6"},{"groupId":"OG001","value":"9.2","lowerLimit":"6.2","upperLimit":"11.3"}]}]}]},{"type":"SECONDARY","title":"Trough Concentrations (Ctrough) of Dacomitinib.","description":"Mean Ctrough values of dacomitinib observed from Cycle 2 through 5, Day 1 for dose compliant participants.","populationDescription":"Participants treated with dacomitinib with at least one measured plasma concentration.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Trough Plasma Concentration (ng/mL)","timeFrame":"Baseline up to Cycle 5 Day 1","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"317"}]}],"classes":[{"title":"Cycle (C) 2 Day (D) 1 (n=317)","categories":[{"measurements":[{"groupId":"OG000","value":"61.0102","spread":"77"}]}]},{"title":"C3D1 (n=175)","categories":[{"measurements":[{"groupId":"OG000","value":"46.5229","spread":"97"}]}]},{"title":"C4D1 (n=131)","categories":[{"measurements":[{"groupId":"OG000","value":"44.2708","spread":"86"}]}]},{"title":"C5D1 (n=95)","categories":[{"measurements":[{"groupId":"OG000","value":"38.0307","spread":"83"}]}]}]},{"type":"SECONDARY","title":"Trough Concentrations (Ctrough) of PF-05199265.","description":"Mean Ctrough values of PF-05199265 observed from Cycle 2 through 5, Day 1 for dose compliant participants.","populationDescription":"Participants treated with dacomitinib with at least one measured plasma concentration.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Trough Plasma Concentration (ng/mL)","timeFrame":"Baseline up to Cycle 5 Day 1","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"323"}]}],"classes":[{"title":"Cycle (C) 2 Day (D) 1 (n=323)","categories":[{"measurements":[{"groupId":"OG000","value":"6.3695","spread":"129"}]}]},{"title":"C3D1 (n=179)","categories":[{"measurements":[{"groupId":"OG000","value":"5.8706","spread":"123"}]}]},{"title":"C4D1 (n=136)","categories":[{"measurements":[{"groupId":"OG000","value":"6.4380","spread":"116"}]}]},{"title":"C5D1 (n=100)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5353","spread":"118"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough Patient Reported Disease Symptoms.","description":"TTD defined as the time from first dose (baseline) to the first time a patient's score in pain, dyspnea, fatigue or cough from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-LC13) increased by ≥10 points. A ≥10 point increase in score had to be maintained for ≥2 consecutive cycles for the symptom to be considered deteriorated. Participants were censored at the last time when they completed an assessment for pain, dyspnea, fatigue or cough if they had not deteriorated. A 10 point or higher change in the score is perceived by participants as clinically significant.","populationDescription":"The PRO analysis set included all participants who started treatment and completed the baseline and at least 1 post-dosing PRO assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"424"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.9"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.9","upperLimit":"1.4"}]}]}]},{"type":"SECONDARY","title":"Mean and Difference in Mean in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Scores ranged from 0-100 where a higher score indicated a better level of quality of life. Overall scores present the mean score for that scale from all time-point data.","populationDescription":"The PRO analysis set included all participants who started treatment and completed the baseline and at least 1 post-dosing PRO assessment.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"QLQ-C30 Global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"56.4068","lowerLimit":"54.631","upperLimit":"58.183"},{"groupId":"OG001","value":"58.3425","lowerLimit":"56.554","upperLimit":"60.131"}]}]},{"title":"QLQ-C30 Cognitive Functioning","categories":[{"measurements":[{"groupId":"OG000","value":"83.8980","lowerLimit":"82.275","upperLimit":"85.521"},{"groupId":"OG001","value":"83.0913","lowerLimit":"81.461","upperLimit":"84.722"}]}]},{"title":"QLQ-C30 Emotional Functioning","categories":[{"measurements":[{"groupId":"OG000","value":"79.1982","lowerLimit":"77.390","upperLimit":"81.007"},{"groupId":"OG001","value":"78.4682","lowerLimit":"76.658","upperLimit":"80.279"}]}]},{"title":"QLQ-C30 Physical Functioning","categories":[{"measurements":[{"groupId":"OG000","value":"75.2138","lowerLimit":"73.250","upperLimit":"77.210"},{"groupId":"OG001","value":"73.6849","lowerLimit":"71.719","upperLimit":"75.651"}]}]},{"title":"QLQ-C30 Role Functioning","categories":[{"measurements":[{"groupId":"OG000","value":"69.3252","lowerLimit":"66.771","upperLimit":"71.879"},{"groupId":"OG001","value":"68.1033","lowerLimit":"65.553","upperLimit":"70.653"}]}]},{"title":"QLQ-C30 Social Functioning","categories":[{"measurements":[{"groupId":"OG000","value":"74.7868","lowerLimit":"72.371","upperLimit":"77.203"},{"groupId":"OG001","value":"76.2839","lowerLimit":"73.864","upperLimit":"78.703"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Global QoL. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.9357","ciPctValue":"95","ciLowerLimit":"-4.278","ciUpperLimit":"0.407","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 cognitive functioning. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"0.8067","ciPctValue":"95","ciLowerLimit":"-1.312","ciUpperLimit":"2.926","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 emotional functioning. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model","paramValue":"0.7300","ciPctValue":"95","ciLowerLimit":"-1.575","ciUpperLimit":"3.035","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 physical functioning. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"1.5289","ciPctValue":"95","ciLowerLimit":"-0.756","ciUpperLimit":"3.814","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 role functioning. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"1.2219","ciPctValue":"95","ciLowerLimit":"-1.975","ciUpperLimit":"4.419","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 social functioning. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.4970","ciPctValue":"95","ciLowerLimit":"-4.575","ciUpperLimit":"1.581","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."}]},{"type":"SECONDARY","title":"Mean and Difference in Mean in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30.","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Scores ranged from 0-100 where a higher score indicated a greater degree of symptoms/problems. Overall scores present the mean score for that scale from all time-point data.","populationDescription":"The PRO analysis set included all participants who started treatment and completed the baseline and at least 1 post-dosing PRO assessment.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"QLQ-C30 Appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"28.5960","lowerLimit":"25.841","upperLimit":"31.351"},{"groupId":"OG001","value":"27.3109","lowerLimit":"24.532","upperLimit":"30.090"}]}]},{"title":"QLQ-C30 Constipation","categories":[{"measurements":[{"groupId":"OG000","value":"8.2496","lowerLimit":"6.392","upperLimit":"10.108"},{"groupId":"OG001","value":"14.1726","lowerLimit":"12.299","upperLimit":"16.046"}]}]},{"title":"QLQ-C30 Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"38.8641","lowerLimit":"36.303","upperLimit":"41.425"},{"groupId":"OG001","value":"18.6077","lowerLimit":"16.017","upperLimit":"21.198"}]}]},{"title":"QLQ-C30 Dysponea","categories":[{"measurements":[{"groupId":"OG000","value":"28.3313","lowerLimit":"25.736","upperLimit":"30.927"},{"groupId":"OG001","value":"32.8812","lowerLimit":"30.282","upperLimit":"35.480"}]}]},{"title":"QLQ-C30 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"35.0885","lowerLimit":"32.848","upperLimit":"37.329"},{"groupId":"OG001","value":"36.7469","lowerLimit":"34.494","upperLimit":"38.999"}]}]},{"title":"QLQ-C30 Financial Difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"20.0597","lowerLimit":"17.760","upperLimit":"22.360"},{"groupId":"OG001","value":"20.0597","lowerLimit":"17.760","upperLimit":"22.360"}]}]},{"title":"QLQ-C30 Insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"19.7903","lowerLimit":"17.413","upperLimit":"22.168"},{"groupId":"OG001","value":"24.6615","lowerLimit":"22.276","upperLimit":"27.046"}]}]},{"title":"QLQ-C30 Nausea and Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"9.1438","lowerLimit":"7.759","upperLimit":"10.528"},{"groupId":"OG001","value":"9.6362","lowerLimit":"8.208","upperLimit":"11.065"}]}]},{"title":"QLQ-C30 Pain","categories":[{"measurements":[{"groupId":"OG000","value":"25.1850","lowerLimit":"22.867","upperLimit":"27.503"},{"groupId":"OG001","value":"24.8754","lowerLimit":"22.551","upperLimit":"27.200"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Appetite loss. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"1.2851","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.416","ciUpperLimit":"4.986","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Constipation. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-5.9230","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.432","ciUpperLimit":"-3.414","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Diarrhea. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model","paramValue":"20.2564","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16.874","ciUpperLimit":"23.639","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Dysponea. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-4.5499","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.719","ciUpperLimit":"-1.381","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Fatigue. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.6584","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.442","ciUpperLimit":"1.125","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Financial Difficulties. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-0.1469","ciPctValue":"95","ciLowerLimit":"-3.056","ciUpperLimit":"2.762","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Insomnia. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-4.8711","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.998","ciUpperLimit":"-1.745","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Nausea and Vomiting. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-0.4924","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.485","ciUpperLimit":"1.500","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for QLQ-C30 Pain. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"0.3096","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.646","ciUpperLimit":"3.265","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."}]},{"type":"SECONDARY","title":"Mean and Difference in Mean in Lung Cancer Symptom Scores as Assessed by the EORTC QLQ- LC13.","description":"The QLQ-LC13 included questions specific to the disease associated symptoms (dyspnea, cough, haemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy, and alopecia), and analgesic use of lung cancer patients. Scores range from 0-100 and a higher score indicates greater degree of symptoms/problems. Overall scores present the mean score for that scale from all time-point data.","populationDescription":"The PRO analysis set included all participants who started treatment and completed the baseline and at least 1 post-dosing PRO assessment.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"424"}]}],"classes":[{"title":"QLQ-LC13 Trouble Swallowing","categories":[{"measurements":[{"groupId":"OG000","value":"10.1934","lowerLimit":"8.360","upperLimit":"12.027"},{"groupId":"OG001","value":"7.5553","lowerLimit":"5.711","upperLimit":"9.400"}]}]},{"title":"QLQ-LC13 Coughing","categories":[{"measurements":[{"groupId":"OG000","value":"28.3790","lowerLimit":"26.037","upperLimit":"30.721"},{"groupId":"OG001","value":"32.6294","lowerLimit":"30.272","upperLimit":"34.986"}]}]},{"title":"QLQ-LC13 Haemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"3.4751","lowerLimit":"2.118","upperLimit":"4.832"},{"groupId":"OG001","value":"4.5515","lowerLimit":"2.615","upperLimit":"6.488"}]}]},{"title":"QLQ-LC13 Sore Mouth","categories":[{"measurements":[{"groupId":"OG000","value":"20.4054","lowerLimit":"18.115","upperLimit":"22.696"},{"groupId":"OG001","value":"11.0509","lowerLimit":"8.731","upperLimit":"13.371"}]}]},{"title":"QLQ-LC13 Shortness of Breath","categories":[{"measurements":[{"groupId":"OG000","value":"27.1651","lowerLimit":"25.161","upperLimit":"29.169"},{"groupId":"OG001","value":"28.3413","lowerLimit":"26.346","upperLimit":"30.337"}]}]},{"title":"QLQ-LC13 Peripheral Neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"19.4905","lowerLimit":"17.222","upperLimit":"21.759"},{"groupId":"OG001","value":"20.1284","lowerLimit":"17.850","upperLimit":"22.407"}]}]},{"title":"QLQ-LC13 Alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"14.8327","lowerLimit":"11.848","upperLimit":"17.818"},{"groupId":"OG001","value":"16.1963","lowerLimit":"13.220","upperLimit":"19.173"}]}]},{"title":"QLQ-LC13 Pain in Chest","categories":[{"measurements":[{"groupId":"OG000","value":"16.4268","lowerLimit":"14.335","upperLimit":"18.518"},{"groupId":"OG001","value":"17.6430","lowerLimit":"15.541","upperLimit":"19.745"}]}]},{"title":"QLQ-LC13 Pain in Arm or Shoulder","categories":[{"measurements":[{"groupId":"OG000","value":"15.9840","lowerLimit":"13.864","upperLimit":"18.104"},{"groupId":"OG001","value":"17.1315","lowerLimit":"14.989","upperLimit":"19.274"}]}]},{"title":"QLQ-LC13 Pain in other Parts","categories":[{"measurements":[{"groupId":"OG000","value":"21.5437","lowerLimit":"19.020","upperLimit":"24.067"},{"groupId":"OG001","value":"22.6124","lowerLimit":"20.060","upperLimit":"25.165"}]}]},{"title":"QLQ-LC13 Any Med for Pain","categories":[{"measurements":[{"groupId":"OG000","value":"61.8437","lowerLimit":"58.169","upperLimit":"65.519"},{"groupId":"OG001","value":"61.8115","lowerLimit":"58.038","upperLimit":"65.585"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Trouble Swallowing as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"2.6381","ciPctValue":"95","ciLowerLimit":"0.172","ciUpperLimit":"5.104","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Coughing as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-4.2504","ciPctValue":"95","ciLowerLimit":"-7.178","ciUpperLimit":"-1.322","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Haemoptysis as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model","paramValue":"-1.0764","ciPctValue":"95","ciLowerLimit":"-3.997","ciUpperLimit":"1.845","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Sore Mouth as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"9.3545","ciPctValue":"95","ciLowerLimit":"6.211","ciUpperLimit":"12.497","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Shortness of Breath as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.1762","ciPctValue":"95","ciLowerLimit":"-3.560","ciUpperLimit":"1.208","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Peripheral Neuropathy as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-0.6378","ciPctValue":"95","ciLowerLimit":"-3.684","ciUpperLimit":"2.408","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Alopecia as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.3637","ciPctValue":"95","ciLowerLimit":"-4.546","ciUpperLimit":"1.819","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Pain in Chest as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.2163","ciPctValue":"95","ciLowerLimit":"-3.885","ciUpperLimit":"1.452","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Pain in Arm or Shoulder as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.1475","ciPctValue":"95","ciLowerLimit":"-3.902","ciUpperLimit":"1.607","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Pain Other Parts as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-1.0687","ciPctValue":"95","ciLowerLimit":"-4.488","ciUpperLimit":"2.351","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for Any Med for Pain as Assessed by the EORTC-QLQ-LC13. Estimated change from baseline was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-LC13 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"0.0322","ciPctValue":"95","ciLowerLimit":"-4.847","ciUpperLimit":"4.911","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."}]},{"type":"SECONDARY","title":"Mean and Difference in Mean of the EuroQoL-5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Score","description":"The EQ-5D is a validated and reliable self-report preference-based measure developed by the EuroQoL Group to assess health-related quality of life. It consists of the EQ-5D descriptive system and a visual analogue scale-the EQ VAS. The EQ-5D descriptive system measures a participants' health state on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels, reflecting \"no health problems,\" \"moderate health problems,\" and \"extreme health problems.\" The EQ VAS records the respondent's self-rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).","populationDescription":"The PRO analysis set included all participants who started treatment and completed the baseline and at least 1 post-dosing PRO assessment.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale.","timeFrame":"Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.","groups":[{"id":"OG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."},{"id":"OG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"424"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1908","lowerLimit":"63.519","upperLimit":"66.863"},{"groupId":"OG001","value":"65.5794","lowerLimit":"63.908","upperLimit":"67.250"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis presented for EQ-5D VAS. Mean difference was from a repeated measures mixed-effects model with an intercept term, treatment, treatment-by-time interaction, and baseline EORTC QLQ-C30 subscale baseline score (intercept and time from first dose are included as random effects). Confidence intervals provided were not adjusted for multiplicity.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Repeated measures mixed-effects model.","paramValue":"-0.3886","ciPctValue":"95","ciLowerLimit":"-2.413","ciUpperLimit":"1.636","estimateComment":"This analysis represents the mean difference between the dacomitinib arm (Arm A) and the erlotinib arm (Arm B)."}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"AE reporting period is from 1st dose of study drug through 28 days after last dose of study drug. SAE reporting period is from informed consent through 28 days after last dose of study drug. The longest duration of treatment in this study was 48 weeks.","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","eventGroups":[{"id":"EG000","title":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","description":"Participants randomized to Arm A received dacomitinib 45 mg orally once daily and erlotinib 150 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death.","seriousNumAffected":178,"seriousNumAtRisk":436,"otherNumAffected":424,"otherNumAtRisk":436},{"id":"EG001","title":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","description":"Participants randomized to Arm B received erlotinib 150 mg orally once daily and dacomitinib 45 mg placebo orally once daily. Participants began treatment within 3 days after randomization and continued treatment without breaks until they experienced unacceptable toxicity, tumor progression, or death.","seriousNumAffected":169,"seriousNumAtRisk":436,"otherNumAffected":417,"otherNumAtRisk":436}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":8,"numAtRisk":436}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Splenic infarction","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Retinal artery embolism","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":436},{"groupId":"EG001","numAffected":7,"numAtRisk":436}]},{"term":"Diverticulum intestinal haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":4,"numAtRisk":436}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pneumoperitoneum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Retroperitoneal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Condition aggravated","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":436},{"groupId":"EG001","numAffected":48,"numAtRisk":436}]},{"term":"Drug interaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":4,"numAtRisk":436}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":10,"numAtRisk":436}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Abdominal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Acne pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":436},{"groupId":"EG001","numAffected":15,"numAtRisk":436}]},{"term":"Pneumonia pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Incisional hernia","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Aspiration bronchial","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Blood calcium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":4,"numAtRisk":436}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":436},{"groupId":"EG001","numAffected":6,"numAtRisk":436}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Chondrocalcinosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Lung squamous cell carcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Metastases to liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Metastatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Squamous cell carcinoma of lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Hypotonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Calculus ureteric","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":436},{"groupId":"EG001","numAffected":8,"numAtRisk":436}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Pulmonary alveolar haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":3,"numAtRisk":436}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":436},{"groupId":"EG001","numAffected":5,"numAtRisk":436}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Exfoliative rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Rash generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hospitalisation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Internal fixation of fracture","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":2,"numAtRisk":436}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":1,"numAtRisk":436}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":436},{"groupId":"EG001","numAffected":43,"numAtRisk":436}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":436},{"groupId":"EG001","numAffected":10,"numAtRisk":436}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":436},{"groupId":"EG001","numAffected":5,"numAtRisk":436}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":436},{"groupId":"EG001","numAffected":20,"numAtRisk":436}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":436},{"groupId":"EG001","numAffected":8,"numAtRisk":436}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":43,"numAtRisk":436},{"groupId":"EG001","numAffected":59,"numAtRisk":436}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":322,"numAtRisk":436},{"groupId":"EG001","numAffected":217,"numAtRisk":436}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":436},{"groupId":"EG001","numAffected":13,"numAtRisk":436}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":436},{"groupId":"EG001","numAffected":16,"numAtRisk":436}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":436},{"groupId":"EG001","numAffected":16,"numAtRisk":436}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":11,"numAtRisk":436}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":90,"numAtRisk":436},{"groupId":"EG001","numAffected":81,"numAtRisk":436}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":81,"numAtRisk":436},{"groupId":"EG001","numAffected":52,"numAtRisk":436}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":71,"numAtRisk":436},{"groupId":"EG001","numAffected":70,"numAtRisk":436}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":436},{"groupId":"EG001","numAffected":59,"numAtRisk":436}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":436},{"groupId":"EG001","numAffected":36,"numAtRisk":436}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":78,"numAtRisk":436},{"groupId":"EG001","numAffected":92,"numAtRisk":436}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":11,"numAtRisk":436}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":7,"numAtRisk":436}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":436},{"groupId":"EG001","numAffected":28,"numAtRisk":436}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":436},{"groupId":"EG001","numAffected":29,"numAtRisk":436}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":436},{"groupId":"EG001","numAffected":21,"numAtRisk":436}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":436},{"groupId":"EG001","numAffected":36,"numAtRisk":436}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":436},{"groupId":"EG001","numAffected":7,"numAtRisk":436}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":436},{"groupId":"EG001","numAffected":14,"numAtRisk":436}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":5,"numAtRisk":436}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":436},{"groupId":"EG001","numAffected":20,"numAtRisk":436}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":94,"numAtRisk":436},{"groupId":"EG001","numAffected":44,"numAtRisk":436}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":436},{"groupId":"EG001","numAffected":5,"numAtRisk":436}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":436},{"groupId":"EG001","numAffected":12,"numAtRisk":436}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":436},{"groupId":"EG001","numAffected":10,"numAtRisk":436}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":436},{"groupId":"EG001","numAffected":22,"numAtRisk":436}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":436},{"groupId":"EG001","numAffected":21,"numAtRisk":436}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":436},{"groupId":"EG001","numAffected":11,"numAtRisk":436}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":436},{"groupId":"EG001","numAffected":13,"numAtRisk":436}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":436},{"groupId":"EG001","numAffected":38,"numAtRisk":436}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":138,"numAtRisk":436},{"groupId":"EG001","numAffected":119,"numAtRisk":436}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":436},{"groupId":"EG001","numAffected":14,"numAtRisk":436}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":436},{"groupId":"EG001","numAffected":16,"numAtRisk":436}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":436},{"groupId":"EG001","numAffected":21,"numAtRisk":436}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":436},{"groupId":"EG001","numAffected":13,"numAtRisk":436}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":436},{"groupId":"EG001","numAffected":10,"numAtRisk":436}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":436},{"groupId":"EG001","numAffected":30,"numAtRisk":436}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":436},{"groupId":"EG001","numAffected":11,"numAtRisk":436}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":436},{"groupId":"EG001","numAffected":8,"numAtRisk":436}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":436},{"groupId":"EG001","numAffected":26,"numAtRisk":436}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":436},{"groupId":"EG001","numAffected":25,"numAtRisk":436}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":436},{"groupId":"EG001","numAffected":22,"numAtRisk":436}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":436},{"groupId":"EG001","numAffected":20,"numAtRisk":436}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":436},{"groupId":"EG001","numAffected":25,"numAtRisk":436}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":436},{"groupId":"EG001","numAffected":73,"numAtRisk":436}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":76,"numAtRisk":436},{"groupId":"EG001","numAffected":81,"numAtRisk":436}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":436},{"groupId":"EG001","numAffected":9,"numAtRisk":436}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":436},{"groupId":"EG001","numAffected":23,"numAtRisk":436}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":436},{"groupId":"EG001","numAffected":37,"numAtRisk":436}]},{"term":"Nasal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":0,"numAtRisk":436}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":8,"numAtRisk":436}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":436},{"groupId":"EG001","numAffected":5,"numAtRisk":436}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":436},{"groupId":"EG001","numAffected":12,"numAtRisk":436}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":436},{"groupId":"EG001","numAffected":7,"numAtRisk":436}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":436},{"groupId":"EG001","numAffected":18,"numAtRisk":436}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":81,"numAtRisk":436},{"groupId":"EG001","numAffected":88,"numAtRisk":436}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":86,"numAtRisk":436},{"groupId":"EG001","numAffected":84,"numAtRisk":436}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":436},{"groupId":"EG001","numAffected":21,"numAtRisk":436}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":436},{"groupId":"EG001","numAffected":7,"numAtRisk":436}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":436},{"groupId":"EG001","numAffected":54,"numAtRisk":436}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":218,"numAtRisk":436},{"groupId":"EG001","numAffected":203,"numAtRisk":436}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":436},{"groupId":"EG001","numAffected":12,"numAtRisk":436}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":436},{"groupId":"EG001","numAffected":10,"numAtRisk":436}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":436},{"groupId":"EG001","numAffected":19,"numAtRisk":436}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Hong Kong"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C525726","term":"dacomitinib"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}